A nonprofit led by the co-founder and former CEO of 23andMe outbid competitors for nearly all of the company’s assets.

Anne Wojcicki's winning bid to reclaim control of 23andMe doesn't necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

TTAM Research Institute - 23andMe's co-founder and former CEO Anne Wojcicki's new company - is the winner in a final round of ...

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

A 23andMe booth at a genealogical event. The Canadian and British commissioners found the company did not have adequate ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Mark Field joins the DNA sequencing giant after six years at Insulet, which makes devices for people with diabetes.

Study shows >95% success rate, validating BE-Smart for use with esophageal brush cytology. UNIONDALE, NY, June 17, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the "Company” or ...

The stratospheric balloons fly higher than airplanes, allowing them to map large disaster areas faster and cheaper than planes or drones.

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...